恶性血液病血清甲状腺激素水平的变化

恶性血液病血清甲状腺激素水平的变化薛梅甲状腺功能异常并非甲状腺疾病所特有，许多非甲状腺疾病也可出现此变化，本文测定了３１例血液系统恶性疾病血清甲状腺激素的浓度，现将结果报告如下。材料和方法一、对象正常组３０例，平均年龄３１．７２岁（２０～４８岁）。病...     

急性白血病患者血清甲状腺激素的测定及意义

甲状腺激素与细胞生长发育密切相关,血清甲状腺浓度异常并非甲状腺疾病所特有,许多非甲状腺疾病如饥饿、营养不良、糖尿病、肝硬化、尿毒症、急性心肌梗死、恶性肿瘤等,都可出现T3浓度降低,而临床上表现为甲状腺功能正常,被称为"低T3综合征"[1].现将100例急性白血病患者血清甲状腺水平变化进行分析,以探讨其变化及意义.     

恶性血液病患者血清免疫抑制酸性蛋白的测定及临床意义

目的：分析恶性血液病患者血甭免疫抑制酸性蛋白（ＩＡＰ）的变化及临床意义。方法：应用单向免疫琼脂扩散法检测５０例恶性血液病和１５例非恶性血液病２者血清ＩＡＰ水平。结果：垩是血液病患者血清ＩＡＰ水平明显增高,与健康对照组相比有差异（Ｐ〈０．０１＿。非恶性血液病患者与健康对照组无统计学差异。动态观察急慢性白血病不同病期ＩＡＰ变化表明,初始与未缓解病人ＩＡＰ增高明显,缓解期水平下降,ＩＡＰ持续增高病人往往     

血清甲状腺激素水平的检测在乳腺癌患者中的临床意义

目的:分析乳腺癌患者血清甲状腺激素水平的检测及临床意义。方法:收集恶性乳腺肿瘤患者40例（恶性乳腺肿瘤组）、良性乳腺肿瘤患者46例（良性乳腺肿瘤组）与健康人群46例（对照组）,检测血清总三碘甲状腺原氨酸(T3)、游离总三碘甲状腺原氨酸(FT3)、总甲状腺激素(T4)、游离甲状腺素(FT4)、促甲状腺素(TSH)及甲状腺过氧化物酶抗体(TPO-Ab)的水平,并分析其与乳腺癌临床病理因素的关系。结果:恶性乳腺肿瘤组T3水平明显低于对照组与良性乳腺肿瘤组(P<0.05),且与肿瘤大小、临床分期有关(P<0.05);恶性乳腺肿瘤组的TPO-Ab阳性表达率明显高于良性乳腺肿瘤组和对照组(P<0.05),且与肿瘤大小、TNM分期、ER及PR表达有关(P<0.05)。结论:乳腺癌患者血清甲状腺激素水平与患者的病情严重程度相关,有助于评估病情和判断预后。     

自体外周血造血干细胞移植治疗恶性血液病

 目的 探讨自体外周血造血干细胞移植（APBSCT）在恶性血液病治疗中的疗效及安全性。方法 对8例具有临床预后不良因素的恶性血液病患者进行APBSCT。结果 全部移植患者造血功能获得满意重建,1例霍奇金淋巴瘤（HD）患者因出现肝静脉闭塞综合征经抢救无效死亡、3例急性粒细胞性白血病患者分别于移植后4、10、12个月疾病复发死亡,1例T淋巴母细胞淋巴瘤患者在移植后3个月发展成为淋巴瘤白血病,经治疗无效死亡。结论 急性白血病在CR1期行APBSCT非治疗最佳选择,对于高危预后不良因素的恶性淋巴瘤患者APBSCT是安全有效的方法。     

乳腺癌与甲状腺疾病相关性的临床研究

 目的　探讨乳腺癌患者自身免疫与非自身免疫甲状腺疾病的发病情况。方法　选择100例乳腺癌手术患者,以同期相对应年龄无乳腺疾病及甲状腺疾病病史女性100名为对照组,通过临床检查、B型超声、甲状腺素及抗体水平检查、细针穿刺活组织检查等对比甲状腺疾病的发病情况。结果　乳腺癌患者抗甲状腺过氧化物酶抗体明显高于对照组[（104.56±21.54）U／ml比（22.16±4.65）U／ml,P＝0.030]。乳腺癌组自身免疫与非自身免疫甲状腺疾病的发病率高于对照组[38 %（38／100）比17 %（17／100）,P＝0.0009;26 %（26／100）与9 %（9／100）,P＝0.0016]。结论　乳腺癌患者的自身免疫与非自身免疫甲状腺疾病的发病率高于非乳腺癌者。     

恶性血液病血浆内皮素与多脏功能衰竭的关系

作者采用放射疫免分析法，测定了６３例恶性血液病患者（其中３３例伴多脏器功能衰竭，３０例无多脏器功能衰竭）及３０例正常人的血浆内皮素水平。结果表明：恶性血液病伴在功能衰竭者血浆内皮素水平明显高于无多脏器功能衰竭者和正常人。恶性血液病血浆内皮素水平随受累脏器的增多而增高，死亡率也随之升高。提示：恶性血液病发生多脏器功能衰竭伴有明显的血管收缩和微循环紊乱。动态监测血浆内皮素水平可作为对恶性血液病疗效判断     

恶性血液病血清腺苷脱氨酶活性测定

作者检测了１０６例恶性血液病血清腺苷脱氨酶活性。结果显示白血病、恶性淋巴瘤、多发性骨髓瘤、骨髓增生异常综合征和恶性组织细胞病的血清腺苷脱氨酶活性均较健康正常人明显增高，腺苷脱氨酶活性与体内瘤细胞负荷有一定关系，并随病情的缓解而下降。提示动态测定血清腺苷脱氨酶活性可作为恶性血液病病情监测和预后判断的一个指标。     

恶性血液病血浆内皮素与多脏器功能衰竭的关系

作者采用放射免疫分析法，测定了６３例恶性血液病患者（其中３３例伴多脏器功能衰竭，３０例无多脏器功能衰竭）及３０例正常人的血浆内皮素水平。结果表明：恶性血液病伴多脏器功能衰竭者血浆内皮素水平明显高于无多脏器功能衰竭者和正常人。恶性血液病血浆内皮素水平随受累脏器的增多而增高，死亡率也随之升高。提示：恶性血液病发生多脏器功能衰竭伴有明显的血管收缩和微循环紊乱。动态监测血浆内皮素水平可作为对恶性血液病疗效判断及预后估计的一个指标。     

白血病及恶性淋巴瘤患者血清CER检测及临床意义

目的 探讨急、慢性白血病、恶性淋巴瘤患者血清铜蓝蛋白ＣＥＲ水平变化及临床意义。方法：用免疫化学全自动分析仪全自动散色比浊法测定白血病９０例恶性淋巴瘤３２例，良性血液病５１例及正常人４４例的血清铜蓝蛋白ＥＣＲ值。结果 急性白血病组及恶性淋巴瘤组患者血清ＣＥＲ测定值均较正常对照组及良性血液病组明显增高（Ｐ〈０．００１和Ｐ〉０．０１），血清ＣＥＲ在急淋组和急非淋组间无显著性差异（Ｐ〉０．０５），急性白血     

Can Non-Thyroid Illness Syndrome Predict Mortality in Lung Cancer Patients? A Prospective Cohort Study

This study aims to evaluate the incidence of non-thyroid illness syndrome (NTIS) among patients diagnosed as lung cancer and its association with the stage of the disease, Eastern Cooperative Oncology Group (ECOG) performance score, nutritional parameters, and survival. We enrolled 120 patients that 71 of them with newly diagnosed and staged non-small cell lung cancer and 49 of them small-cell lung cancer. The cases were examined for thyroid function tests, ECOG performance score, and nutritional evaluation before treatment. Also, cases were evaluated for their overall survival rates. NTIS was identified in 30 (42 %) of the 71 non-small cell lung cancer patients and 22 (44 %) of the 49 small-cell lung cancer patients. NTIS was more frequent among advanced stage of cases. Serum albumin level, cholesterol level, lymphocyte level, and body mass index were detected to be significantly low and ECOG performance score was significantly high in cases with NTIS when compared to cases without NTIS. NTIS was found to be negatively correlated with body mass index, ECOG performance score, and serum albumin level, and it was positively correlated with disease stage. NTIS was detected significantly as a poor prognostic factor for lung cancer. NTIS was frequently seen in cases with non-small cell lung cancer and small-cell lung cancer. NTIS can be used as a predictor of poor prognosis for lung cancer patients.     

康莱特联合化疗对肿瘤患者细胞免疫影响及生活质量改善的临床研究

目的 :比较康莱特配合化疗与单纯化疗治疗晚期恶性肿瘤患者的疗效、细胞免疫功能和生活质量的改善及血液毒性的改变情况。方法 :采取随机对照分组 ,治疗组 (5 8例 )为康莱特联合化疗 ;对照组 (6 0例 )为单纯化疗。结果 :治疗组有效率 (PR +CR)为 37 93% ,两组相比差异有显著意义 ,P <0 0 5。治疗组免疫功能测定 ,T细胞亚群和NK细胞活性明显高于对照组 ,P <0 0 1。治疗组Karnofsky评分高于对照组 ,P <0 0 5。结论 :康莱特联合化疗可提高化疗疗效 ,减少毒副反应 ,提高患者的细胞免疫功能 ,改善患者生存质量 ,是中、晚期恶性肿瘤患者化疗的良好配伍药物。     

口腔原发恶性淋巴瘤的临床和病理特征分析

目的：口腔原发恶性淋巴瘤较少见,对其临床和病理特征进行总结。方法：回顾性地分析了５５例口腔原发恶性淋巴瘤的临床表现,免疫表型和形态特点。结果：该瘤在口腔的发生部位依次为腭部,牙龈,舌,颊部,口底,大多表现为溃疡状肿的,少数为表面光滑的结节。免疫表型的分析表明２０例为Ｔ淋巴瘤,３０例为Ｂ淋巴瘤,５例Ｔ或Ｂ表型均未检出。     

Genetic Polymorphisms in ERCC1 Gene and Their Association with Response to Radiotherapy in Moroccan Patients with Nasopharyngeal Carcinoma

Objective: Nasopharyngeal carcinoma (NPC) is a severe malignant disease. Despite its low frequency, NPC is very common in North African population. Radiotherapy is the standard therapeutic treatment of NPC. However, radioresistance hampers the success of treatment. At the molecular scale, radioresistance is due to genetic variations involved in DNA repair pathways in NPC patients. Several studies reported that single nucleotide polymorphisms (SNPs) in excision repair cross complementing group 1 (ERCC1) could be associated with radioresistance. In this optic, the present study aimed to evaluate the association between DNA repair gene polymorphisms ERCC1 C8092A and ERCC1 C118T and radiotherapy response of patients with NPC. Methods: A total of 95 patients with confirmed NPC were recruited at the Mohammed VI Center for Cancer Treatment, Casablanca - Morocco between 2016 and 2018. Two single nucleotide polymorphisms in ERCC1 gene were genotyped. Multiple analysis software was used to assess the correlation between these SNPs and radio-therapeutic response. Results: Sequencing of ERCC1 C8092A polymorphism revealed that CC and CA genotypes were found in 51.6% and 45.3% of cases, respectively, whereas the homozygote AA genotype was reported in only 3.1% of cases. For ERCC1 C118T polymorphism, the heterozygote CT genotype was identified in 49.5% of cases. Homozygotes genotypes CC and TT were detected in 17.9% and 32.6% respectively of NPC cases. Of note, no significant association was found between the ERCC1 C8092A polymorphism and response to radiation therapy (p=0.81). Similarly, there was no significant association between the response to radiotherapy and allelic distribution (p=0.56). Likewise, no correlation was observed neither with genotypes (p=0.07) nor with alleles (p=0.09) of ERCC1 C118T polymorphism and response to radiation therapy. Conclusion: Our results clearly showed that ERCC1 C8092A and ERCC1 C118T polymorphisms were not associated with response to radiotherapy in Moroccan NPC patients. Large studies are warranted to confirm the role of these SNPs in therapeutic response of NPC patients.     

Changes in growth, po(2) and ph after exposure to oxamate - studies of 2 human tumor-cell lines growing as multicellular spheroids

The basic metabolism and pO(2) and pH gradients in spheroids were characterized and, in some cases, changed by the addition of the pyruvate analogue oxamate. Two human tumour spheroid types, colon adenocarcinoma HT29 and malignant glioma U118MG, were applied as models. Microelectrode measurements in HT29 spheroids showed steep pO(2) gradients with large differences between surface and center, Delta pO(2), and low central pO(2) values. The HT29 spheroids had rather flat pH gradients. The U118MG spheroids had less steep pO(2) gradients but steeper pH gradients. Determinations of 1-C-14 and 2-C-14 pyruvate oxidation rates, for characterization of the oxidative glucose breakdown as well as of lactate dehydrogenase kinetics, showed consistent results with the microelectrode measurements in that there was high oxidative metabolism in the HT29 spheroids whereas the U118MG spheroids relied more on glycolysis. Western blot investigations of the LDH isoenzyme composition showed different isoenzyme patterns in the two spheroid types with a lack of LDH1 in U118MG spheroids. Addition of 40 mM of oxamate gave decreased 1-C-14- and 2-C-14-pyruvate oxidation rates in the HT29 cells and inhibition of LDH activity in the U118MG cells. Oxamate increased the central pO(2) values in HT29 spheroids and the central pH values in U118MG spheroids. One example of experimental therapy was applied and oxamate acted as a radiation sensitizer in the U118MG system and as a radioprotective substance in the HT29 system. This has to be analysed in more detail.     

Quantitative analysis of nuclear area variation in benign and malignant breast fine needle aspirates.

The measurement of nuclear area was carried out in 30 benign and 32 malignant breast lumps using Omnicon Alpha 500 Image Analyzer. The mean nuclear area of duct cells in malignant group was greater (157.6 +/- 58.64 sq.microns with a peak around 140 sq.microns) and more heterogenous within and amongst cases than observed in duct cells from most of the cases of fibroadenoma (85.05 ae 14.2 sq.microns with a peak around 80 sq.microns). Taking into consideration 110 sq.microns as a differentiating limit, a significant difference was observed between benign and malignant conditions (p). Similarly taking 118 sq.microns as differentiating limit duct cell carcinomas could be divided into two groups i.e. 9(28.1%) cases of small nuclear type with a range of 80-118 sq.microns and 23(71.9%) cases of large nuclear type with a range of 118-320 sq microns .6(18.8%) cases with small nuclei had an overlap with fibroadenoma. Although 13(72.2%) cases of large nuclear type carcinomas had lymph node metastasis as against 4(44.4%) in small nuclear group, the difference was not statistically significant.     

颅内黑色素瘤的诊断与治疗--附五例临床分析及文献复习

为讨论颅内黑色素瘤的临床表现、影像学特征及治疗方法 ,对本科近 13年来治疗的 5例颅内黑色素瘤进行回顾性分析。结果示颅内黑色素瘤的临床表现不具有特征性。影像学上CT表现为高密度或混杂密度 ,增强扫描呈不同程度强化。核磁共振检查 (MRI)表现为短T1短T2 信号 ,也可以因顺磁性黑色素含量不同和瘤内有无出血 ,表现为高、低或混杂信号 ,注射二乙胺五乙酸钆 (GD DTPA)后出现不同程度的强化。 5例患者中 ,3例手术全切 ,1例大部分切除 ,1例未手术。初步研究结果提示 ,颅内黑色素瘤的预后差 ,主张在手术基础上进行包括放疗及化疗的综合治疗     

恶性血液病治疗前后T细胞亚群和NK细胞活性测定分析

目的　检测 46例恶性血液病患者化疗前后外周血T细胞亚群及NK细胞活性 ,观察胸腺肽免疫功能。方法　应用单克隆抗体和流式细胞仪。结果　 (1)恶性血液病患者各项免疫活性细胞表达均低于对照组 ;(2 )晚期和复发型恶性血液病患者各项免疫指标均低于初发型恶性血液病 ;(3 )AL各项免疫指标明显低于其它恶性血液病 ;(4 )治疗后A、B两组比较 ;A组的NK细胞活性明显高于B组 ,A组治疗后CD3 、CD4、CD4/CD8、NK细胞活性明显高于治疗前。结论　T细胞亚群、NK细胞活性在恶性血液病患者中受到抑制并随病情程度而进一步加剧 ,其中AL患者受抑更甚 ,胸腺肽能明显提高恶性血液病患者的细胞免疫功能 ,尤其对NK细胞 ,它是一种低毒高效的生物反应调节剂。     

Angioimmunoblastic lymphadenopathy with disproteinemia associated with carcinoma. Case report and review of the literature

Angioimmunoblastic lymphadenopathy with disproteinemia (AILD) is a rare lymphoproliferative disorder. The clinical course varies and about 15-20% of the patients develop a malignant lymphoma. The association of AILD and carcinoma is very rare: only 4 cases have been reported in the literature. They are reviewed here and 1 case is described. This case is of special interest for the following reasons: (1) the exceptional length of time which elapsed between the diagnosis of AILD and the onset of an adenocarcinoma of the colon (118 months); (2) the long survival (the patient is still alive and well 140 months after the diagnosis of AILD); (3) unlike the cases reviewed, in our patient the carcinoma was diagnosed when AILD was in clinical remission, so a radical treatment was possible. In the cases previously reported, carcinomas arose in the lung (2 patients), pancreas (1 case), and stomach (1 case). The rare association of AILD and carcinoma is probably coincidental; however, the growth of solid tumors of nonlymphoid nature may be related to the impaired T cell function, and should be kept in mind in the management of patients with AILD.     

CD3+CD56+NKT细胞及CD3-CD56+NK细胞在恶性肿瘤患者的临床意义研究

背景与目的细胞毒性淋巴细胞在抗肿瘤免疫效应中发挥着重要作用,CD3 CD56 NKT细胞作为一类新的具有细胞毒性的效应细胞,目前关于其抗肿瘤意义的探讨主要集中于血液系统恶性疾病,而在实体肿瘤中的应用和临床价值研究尚少。本研究旨在初步探讨抗肿瘤细胞CD3 CD56 NKT细胞及CD3-CD56 NK细胞在恶性肿瘤患者外周血的表达状态及其临床意义。方法采用流式细胞术分析118例恶性肿瘤患者(55例肺癌患者和63例乳腺癌患者)及46例健康对照组外周血中的T细胞亚群及CD3 CD56 NKT细胞、CD3-CD56 NK细胞表达。结果恶性肿瘤患者组CD3 CD8 T细胞、CD3 CD56 NKT细胞以及CD3-CD56 NK细胞表达率均明显高于健康对照组(P<0.01)。肺癌患者中以CD3 CD8 T细胞和CD3 CD56 NKT细胞明显增加为主;乳腺癌患者中以CD3 CD56 NKT细胞和CD3-CD56 NK细胞明显增加为主。结论CD3 CD56 NKT细胞在肺癌和乳腺癌患者的抗肿瘤效应中占据重要地位,而CD3 CD8 CTL和CD3-CD56 NK细胞在不同类型肿瘤患者中具有不同的重要性。